Moberg Pharma gives notice of early redemption of bonds with ISIN SE0007953989

STOCKHOLM, April 1st, 2019. On February 12th, 2019, it was announced that Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) has entered into agreement with RoundTable Healthcare Partners and Signet Healthcare Partners to divest the entire commercial operation and that the Company intends to redeem its outstanding bonds 2016/2021 with ISIN SE0007953989 (the “Bonds”) in connection with closing of the transaction. On March 29th, 2019, it was announced that closing of the transaction has taken place and the Company will therefore redeem the Bonds in accordance with the terms and conditions for the Bonds.

On April 1st, 2019, the Company sent an irrevocable notice of early redemption to all directly registered owners and registered authorised nominees (Sw. förvaltare) in the debt register for the Bonds kept by Euroclear Sweden as of March 29th, 2019.

The early redemption date is set to April 29th, 2019. In accordance with the terms and conditions, the Bonds will be redeemed at an amount equal to 104.00 per cent. of the nominal amount (i.e. SEK 1,040,000 per Bond).

The redemption amount, together with accrued and unpaid interest up to and including the early redemption date, will be paid to each person who is registered as owner of Bonds in the debt register maintained by Euroclear Sweden at end of business on April 18th, 2019. In connection with the redemption, the Bonds will be delisted from Nasdaq Stockholm.

This press release is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of the Company.

For additional information, please contact: 
Peter Wolpert, CEO, phone: Sweden: +46 707 35 7135, US: +1 908 432 2203, e-mail: peter.wolpert@mobergpharma.se

Anna Ljung, CFO, phone: +46 707 66 6030, e-mail: anna.ljung@mobergpharma.se

About this information              
The information was submitted for publication, through the contact persons set out above, at 8.30 a.m. (CET) on April 1st, 2019.

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focusing on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset MOB-015 is a novel topical treatment for onychomycosis, for which phase 3 data in 800+ patients is expected in late 2019 in North America, and first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain management in oral mucositis. The clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Tags:

About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit: www.mobergpharma.com.

Contacts